Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zicam is a prominent brand of over-the-counter (OTC) healthcare products specializing in cold shortening and allergy relief. The brand's flagship products utilize zinc-based formulations intended to reduce the duration and severity of the common cold when administered at the onset of symptoms. Zicam Canada manages the distribution and marketing of these products within the Canadian market, including various formats such as rapid melts, nasal swabs, and fruit drops. In December 2020, the brand's parent company, Matrixx Initiatives, was acquired by Church & Dwight for approximately $530 million. Today, Zicam continues to be a leader in the homeopathic cold remedy category across North America.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zicam Canada.